MetaphysicalCells

MetaphysicalCells

Share this post

MetaphysicalCells
MetaphysicalCells
Weekly TechBio News (II)

Weekly TechBio News (II)

Latest News: Phenaros Pharmaceuticals, Acellera Therapeutics, Artificial Inc, Owkin, Innophore, Algorae Pharmaceuticals, Okomera, Ultima Genomics, Araceli Bioscience and many more

Marina T Alamanou's avatar
Marina T Alamanou
Feb 06, 2025
∙ Paid
4

Share this post

MetaphysicalCells
MetaphysicalCells
Weekly TechBio News (II)
1
Share

For today’s latest TechBio news:

  • 🛵 Weekly TechBio News (I)

    Latest News: Lantern Pharma, Insilico Medicine, ThinkCyte, Manas AI, LinkGevity, Certara, Tevogen Bio, Retro Biosciences, Model Medicine and Isomorphic Labs

  • 🛵 Weekly TechBio News (II)

    Latest News: Phenaros Pharmaceuticals, Acellera Therapeutics, Artificial Inc, Owkin, Innophore, Algorae Pharmaceuticals, Okomera, Ultima Genomics, Araceli Bioscience and many more

“The inner fire is the most important thing mankind possesses.”


Edith Södergran

Weekly TechBio News (II)

🪐 Phenaros Pharmaceuticals AB

On January 30, 2025, Phenaros Pharmaceuticals raised a pre-seed funding to further develop its AI-driven drug discovery platform. The round was led by Nordic Science Investments, with additional support from Almi Invest, Monesi and Länsförsäkringar Uppsala, and Phenaros plans to use the funding to expand its robotized facilities, enhance its proprietary data and scale its commercial operations (Swedish AI-driven drug discovery company raises pre-seed round to enhance R&D efforts - ArcticStartup).

Founded in 2021, Phenaros (a spin-off drug discovery company from Uppsala University Sweden and SciLifeLab) combines AI, automation and phenomics (large scale cell morphological profiling) for the discovery of new and repurposing drugs for rare diseases. Apart from pursuing an in-house drug discovery pipeline, they also establish partnerships.

They use Cell Painting when screening disease models for repurposed drugs and discovery of novel leads, and the generated rich data and state-of-the-art AI methods enable them to perform iterative, intelligent screening. They exploit genetic, chemical or biological perturbations that induce distinct cell morphological changes and use them to predict mechanisms of action, target or cellular toxicity. They analyze data by using unsupervised and supervised methods. Basically, they generate thousands of images per experiment, which translate into millions of cells analyzed and billions of morphological features extracted. To support such high amounts of data, they have built a powerful information technology infrastructure for automated image and data storage, image analysis, data analysis and data visualisation.

Latest News 🗞️

Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development

Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances

China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment

Schrödinger adopts Sapio Platform to improve efficiency

Data4Cure Partners With Pfizer to Deliver New Insights With AI and Data-Driven Knowledge Graphs

Singapore develops new AI-powered tool for early dementia screening

BostonGene Contributes to Friends of Cancer Research White Paper Introducing a Novel Process for Companion Diagnostics for Rare Biomarkers and Indications

MetaphysicalCells is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Marina T Alamanou
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share